A BILL 
To provide for quality assurance of COVID–19 
reimbursements and reporting. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. QUALITY ASSURANCE OF COVID–19 REIM-
3
BURSEMENTS AND REPORTING. 
4
(a) IN GENERAL.—Notwithstanding any other provi-
5
sion of law, no Federal funds shall be used for a reim-
6
bursement or payment for— 
7
(1) COVID–19 testing of any individual unless 
8
the request for such reimbursement or payment is 
9
21:59 Feb 06, 2021
H311
2 
•HR 311 IH
accompanied by evidence that the individual was 
1
tested using a test that was approved, cleared, or 
2
authorized under section 510(k), 513, 515, or 564 
3
of the Federal Food, Drug, and Cosmetic Act (21 
4
U.S.C. 360(k), 360c, 360e, 360bbb–3) for COVID– 
5
19 diagnosis; or 
6
(2) COVID–19 treatment of any individual un-
7
less the request for reimbursement or payment is ac-
8
companied by evidence that the person tested posi-
9
tive for COVID–19 using a test that was approved, 
10
cleared, or authorized under section 510(k), 513, 
11
515, or 564 of the Federal Food, Drug, and Cos-
12
metic Act (21 U.S.C. 360(k), 360c, 360e, 360bbb– 
13
3) for COVID–19 diagnosis. 
14
(b) QUALITY ASSURANCE OF REIMBURSEMENTS.— 
15
For purposes of subsection (a), notwithstanding any other 
16
provision of law, the head of any Federal agency author-
17
ized to make a reimbursement or payment for COVID– 
18
19 testing or treatment of individuals shall review each 
19
request presented for such reimbursement or payment 
20
and— 
21
(1) deny any request for such a reimbursement 
22
or payment for COVID–19 testing of an individual 
23
or, if reimbursement or payment has already been 
24
made, cause to be recovered such reimbursement or 
25
21:59 Feb 06, 2021
H311
3 
•HR 311 IH
payment, unless the request is accompanied by evi-
1
dence that the individual was tested using a test 
2
that was approved, cleared, or authorized under sec-
3
tion 510(k), 513, 515, or 564 of the Federal Food, 
4
Drug, and Cosmetic Act (21 U.S.C. 360(k), 360c, 
5
360e, 360bbb–3) for COVID–19 diagnosis as of the 
6
date of the review of the head of the agency; 
7
(2) deny any request for such a reimbursement 
8
or payment for COVID–19 treatment of an indi-
9
vidual or, if reimbursement or payment has already 
10
been made, cause to be recovered such reimburse-
11
ment or payment, unless the request is accompanied 
12
by evidence that the individual tested positive for 
13
COVID–19 using a test that was approved, cleared, 
14
or authorized under section 510(k), 513, 515, or 
15
564 of the Federal Food, Drug, and Cosmetic Act 
16
(21 U.S.C. 360(k), 360c, 360e, 360bbb–3) for 
17
COVID–19 diagnosis as of the date of the review of 
18
the head of the agency; and 
19
(3) provide to the Director of the Centers for 
20
Disease Control and Prevention the results of such 
21
review. 
22
(c) CORRECTION OF REPORTS.—The Director of the 
23
Centers for Disease Control and Prevention shall apply 
24
21:59 Feb 06, 2021
H311
4 
•HR 311 IH
the results provided to the Director under subsection 
1
(b)(3) to— 
2
(1) exclude from the official United States 
3
count of cases of COVID–19 any individual reported 
4
to have been positive for COVID–19 in a request 
5
subject to review in subsection (b) but where the 
6
agency head involved found the request was not ac-
7
companied by evidence that the individual had been 
8
tested positive for COVID–19 using a test that was 
9
approved, cleared, or authorized under section 
10
510(k), 513, 515, or 564 of the Federal Food, 
11
Drug, and Cosmetic Act (21 U.S.C. 360(k), 360c, 
12
360e, 360bbb–3) for diagnosis of COVID–19; and 
13
(2) exclude from the official United States 
14
count of deaths due to COVID–19 any individual 
15
who died and was reported to have been treated or 
16
tested positive for COVID–19 in a request subject to 
17
review under subsection (b) but where the agency 
18
head involved found the request was not accom-
19
panied by evidence that the individual had been test-
20
ed positive for COVID–19 using a test that was ap-
21
proved, cleared, or authorized under section 510(k), 
22
513, 515, or 564 of the Federal Food, Drug, and 
23
Cosmetic Act (21 U.S.C. 360(k), 360c, 360e, 
24
360bbb–3) for diagnosis of COVID–19. 
25
21:59 Feb 06, 2021
H311
5 
•HR 311 IH
(d) PENALTY.—Any person who knowingly reports a 
1
false diagnosis of COVID–19 shall be imprisoned not more 
2
than 10 years and fined under title 18, United States 
3
Code, or both. 
4
Æ 
21:59 Feb 06, 2021
H311
